cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Avrobio Inc
6 own
9 watching
Current Price
$0
$0.03
(3.23%)
logo-avro
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
40.71M
52-Week High
52-Week High
1.9
52-Week Low
52-Week Low
0.56
Average Volume
Average Volume
0.7M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization40.71M
icon52-Week High1.9
icon52-Week Low0.56
iconAverage Volume0.7M
iconDividend Yield--
iconP/E Ratio--
What does the Avrobio Inc do?
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company s product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Avrobio Inc make?
News & Events about Avrobio Inc.
Zolmax
8 months ago
AVROBIO, Inc. (NASDAQ:AVRO Get Rating) Investment analysts at Wedbush issued their Q1 2023 earnings per share estimates for AVROBIO in a report issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.29) per share for the quarter. Wedbush...
Business Wire
9 months ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the companys common stock to one...
Ticker Report
10 months ago
Wall Street analysts predict that AVROBIO, Inc. (NASDAQ:AVRO Get Rating) will report earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for AVROBIOs earnings, with estimates ranging from ($0.76) ...
Frequently Asked Questions
Frequently Asked Questions
What is Avrobio Inc share price today?
plus_minus_icon
Can Indians buy Avrobio Inc shares?
plus_minus_icon
How can I buy Avrobio Inc shares from India?
plus_minus_icon
Can Fractional shares of Avrobio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Avrobio Inc stocks?
plus_minus_icon
What is today’s traded volume of Avrobio Inc?
plus_minus_icon
What is today’s market capitalisation of Avrobio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Avrobio Inc?
plus_minus_icon
What percentage is Avrobio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Avrobio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.03
(3.23%)
logo-avro
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00